Imprinting diseases (IDs) are rare congenital disorders caused by aberrant dosages of imprinted genes. Rare IDs are comprised by a group of several distinct disorders that share a great deal of homology in terms of genetic etiologies and symptoms. Disruption of genetic or epigenetic mechanisms can cause issues with regulating the expression of imprinted genes, thus leading to disease. Genetic mutations affect the imprinted genes, duplications, deletions, and uniparental disomy (UPD) are reoccurring phenomena causing imprinting diseases. Epigenetic alterations on methylation marks in imprinting control centers (ICRs) also alters the expression patterns and the majority of patients with rare IDs carries intact but either silenced or overexpressed imprinted genes. Canonical CRISPR/Cas9 editing relying on double-stranded DNA break repair has little to offer in terms of therapeutics for rare IDs. Instead CRISPR/Cas9 can be used in a more sophisticated way by targeting the epigenome. Catalytically dead Cas9 (dCas9) tethered with effector enzymes such as DNA de- and methyltransferases and histone code editors in addition to systems such as CRISPRa and CRISPRi have been shown to have high epigenome editing efficiency in eukaryotic cells. This new era of CRISPR epigenome editors could arguably be a game-changer for curing and treating rare IDs by refined activation and silencing of disturbed imprinted gene expression. This review describes major CRISPR-based epigenome editors and points out their potential use in research and therapy of rare imprinting diseases.

Czech Centre for Phenogenomics Institute of Molecular Genetics of the CAS v v i 252 50 Vestec Czech Republic

Laboratory of Transgenic Models of Diseases Institute of Molecular Genetics of the CAS v v i 252 50 Vestec Czech Republic

Zobrazit více v PubMed

Jinek M., Chylinski K., Fonfara I., Hauer M., Doudna J.A., Charpentier E. A Programmable Dual-RNA-Guided DNA Endonuclease in Adaptive Bacterial Immunity. Science. 2012;337:816–821. doi: 10.1126/science.1225829. PubMed DOI PMC

Jinek M., Jiang F., Taylor D.W., Sternberg S.H., Kaya E., Ma E., Anders C., Hauer M., Zhou K., Lin S., et al. Structures of Cas9 Endonucleases Reveal RNA-Mediated Conformational Activation. Science. 2014;343:1247997. doi: 10.1126/science.1247997. PubMed DOI PMC

Gilbert L.A., Horlbeck M.A., Adamson B., Villalta J.E., Chen Y., Whitehead E.H., Guimaraes C., Panning B., Ploegh H.L., Bassik M.C., et al. Genome-Scale CRISPR-Mediated Control of Gene Repression and Activation. Cell. 2014;159:647–661. doi: 10.1016/j.cell.2014.09.029. PubMed DOI PMC

Kato T., Hara S., Goto Y., Ogawa Y., Okayasu H., Kubota S., Tamano M., Terao M., Takada S. Creation of mutant mice with megabase-sized deletions containing custom-designed breakpoints by means of the CRISPR/Cas9 system. Sci. Rep. 2017;7:59. doi: 10.1038/s41598-017-00140-9. PubMed DOI PMC

Kitamoto K., Taketani Y., Fujii W., Inamochi A., Toyono T., Miyai T., Yamagami S., Kuroda M., Usui T., Ouchi Y. Generation of mouse model of TGFBI-R124C corneal dystrophy using CRISPR/Cas9-mediated homology-directed repair. Sci. Rep. 2020;10:1–10. doi: 10.1038/s41598-020-58876-w. PubMed DOI PMC

Ran F.A., Hsu P.D., Lin C.Y., Gootenberg J.S., Konermann S., Trevino A.E., Scott D.A., Inoue A., Matoba S., Zhang Y., et al. Double nicking by RNA-guided CRISPR cas9 for enhanced genome editing specificity. Cell. 2013;154:1380–1389. doi: 10.1016/j.cell.2013.08.021. PubMed DOI PMC

Chen X., Tasca F., Wang Q., Liu J., Janssen J.M., Brescia M.D., Bellin M., Szuhai K., Kenrick J., Frock R.L., et al. Expanding the editable genome and CRISPR-Cas9 versatility using DNA cutting-free gene targeting based on in trans paired nicking. Nucleic Acids Res. 2020;48:974–995. doi: 10.1093/nar/gkz1121. PubMed DOI PMC

Vigouroux A., Oldewurtel E., Cui L., Bikard D., Teeffelen S. Tuning dCas9’s ability to block transcription enables robust, noiseless knockdown of bacterial genes. Mol. Syst. Biol. 2018;14 doi: 10.15252/msb.20177899. PubMed DOI PMC

Perez-Pinera P., Kocak D.D., Vockley C.M., Adler A.F., Kabadi A.M., Polstein L.R., Thakore P.I., Glass K.A., Ousterout D.G., Leong K.W., et al. RNA-guided gene activation by CRISPR-Cas9–based transcription factors. Nat. Methods. 2013;10:973–976. doi: 10.1038/nmeth.2600. PubMed DOI PMC

Maeder M.L., Linder S.J., Cascio V.M., Fu Y., Ho Q.H., Joung J.K. CRISPR RNA-guided activation of endogenous human genes. Nat. Methods. 2013;10:977–979. doi: 10.1038/nmeth.2598. PubMed DOI PMC

Li E. Chromatin modification and epigenetic reprogramming in mammalian development. Nat. Rev. Genet. 2002;3:662–673. doi: 10.1038/nrg887. PubMed DOI

Inbar-Feigenberg M., Choufani S., Butcher D.T., Roifman M., Weksberg R. Basic concepts of epigenetics. Fertil. Steril. 2013;99:607–615. doi: 10.1016/j.fertnstert.2013.01.117. PubMed DOI

Jones P.A. Functions of DNA methylation: Islands, start sites, gene bodies and beyond. Nat. Rev. Genet. 2012;13:484–492. doi: 10.1038/nrg3230. PubMed DOI

Rasmussen K.D., Helin K. Role of TET enzymes in DNA methylation, development, and cancer. Genes Dev. 2016;30:733–750. doi: 10.1101/gad.276568.115. PubMed DOI PMC

Okano M., Bell D.W., Haber D.A., Li E. DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell. 1999;99:247–257. doi: 10.1016/S0092-8674(00)81656-6. PubMed DOI

Bourc’his D., Xu G.L., Lin C.S., Bollman B., Bestor T.H. Dnmt3L and the establishment of maternal genomic imprints. Science. 2001;294:2536–2539. doi: 10.1126/science.1065848. PubMed DOI

Sadakierska-Chudy A., Kostrzewa R.M., Filip M. A Comprehensive View of the Epigenetic Landscape Part I: DNA Methylation, Passive and Active DNA Demethylation Pathways and Histone Variants. Neurotox. Res. 2015;27:84–97. doi: 10.1007/s12640-014-9497-5. PubMed DOI PMC

Hill P.W.S., Amouroux R., Hajkova P. DNA demethylation, Tet proteins and 5-hydroxymethylcytosine in epigenetic reprogramming: An emerging complex story. Genomics. 2014;104:324–333. doi: 10.1016/j.ygeno.2014.08.012. PubMed DOI

Cortellino S., Xu J., Sannai M., Moore R., Caretti E., Coz M.L., Devarajan K., Wessels A., Soprano D., Abramowitz K., et al. Demethylation by Linked Deamination-Base Excision Repair. Cell. 2011;146:67–79. doi: 10.1016/j.cell.2011.06.020. PubMed DOI PMC

Nabel C.S., Jia H., Ye Y., Shen L., Goldschmidt H.L., Stivers J.T., Zhang Y., Kohli R.M. AID/APOBEC deaminases disfavor modified cytosines implicated in DNA demethylation. Nat. Chem. Biol. 2012;8:751–758. doi: 10.1038/nchembio.1042. PubMed DOI PMC

Dizdaroglu M., Bergtold D.S. Characterization of free radical-induced base damage in DNA at biologically relevant levels. Anal. Biochem. 1986;156:182–188. doi: 10.1016/0003-2697(86)90171-5. PubMed DOI

Barski A., Cuddapah S., Cui K., Roh T.Y., Schones D.E., Wang Z., Wei G., Chepelev I., Zhao K. High-Resolution Profiling of Histone Methylations in the Human Genome. Cell. 2007;129:823–837. doi: 10.1016/j.cell.2007.05.009. PubMed DOI

Koch C.M., Andrews R.M., Flicek P., Dillon S.C., Karaöz U., Clelland G.K., Wilcox S., Beare D.M., Fowler J.C., Couttet P., et al. The landscape of histone modifications across 1% of the human genome in five human cell lines. Genome Res. 2007;17:691–707. doi: 10.1101/gr.5704207. PubMed DOI PMC

Creyghton M.P., Cheng A.W., Welstead G.G., Kooistra T., Carey B.W., Steine E.J., Hanna J., Lodato M.A., Frampton G.M., Sharp P.A., et al. Histone H3K27ac separates active from poised enhancers and predicts developmental state. Proc. Natl. Acad. Sci. USA. 2010;107:21931–21936. doi: 10.1073/pnas.1016071107. PubMed DOI PMC

Liu Y., Liu K., Yin L., Yu Y., Qi J., Shen W.H., Zhu J., Zhang Y., Dong A. H3K4me2 functions as a repressive epigenetic mark in plants. Epigenet. Chromatin. 2019;12:40. doi: 10.1186/s13072-019-0285-6. PubMed DOI PMC

Rosenfeld J.A., Wang Z., Schones D.E., Zhao K., DeSalle R., Zhang M.Q. Determination of enriched histone modifications in non-genic portions of the human genome. BMC Genom. 2009;10:143. doi: 10.1186/1471-2164-10-143. PubMed DOI PMC

Lu D. Epigenetic modification enzymes: Catalytic mechanisms and inhibitors. Acta Pharm. Sin. B. 2013;3:141–149. doi: 10.1016/j.apsb.2013.04.007. DOI

Biswas S., Rao C.M. Epigenetic tools (The Writers, The Readers and The Erasers) and their implications in cancer therapy. Eur. J. Pharmacol. 2018;837:8–24. doi: 10.1016/j.ejphar.2018.08.021. PubMed DOI

Enríquez P. CRISPR-mediated epigenome editing. Yale J. Biol. Med. 2016;89:471–486. PubMed PMC

Surani M.A.H., Barton S.C., Norris M.L. Development of reconstituted mouse eggs suggests imprinting of the genome during gametogenesis. Nature. 1984;308:548–550. doi: 10.1038/308548a0. PubMed DOI

McGrath J., Solter D. Completion of mouse embryogenesis requires both the maternal and paternal genomes. Cell. 1984;37:179–183. doi: 10.1016/0092-8674(84)90313-1. PubMed DOI

Peters J. The role of genomic imprinting in biology and disease: An expanding view. Nat. Rev. Genet. 2014;15:517–530. doi: 10.1038/nrg3766. PubMed DOI

Williamson C.M., Thomas S., Beechey C.V., Hancock J., Cattanach B.M., Peters J. MRC Harwell, Oxfordshire. World Wide Web Site - Mouse Imprinting Data and References. [(accessed on 3 March 2020)];2013 Available online: http://www.har.mrc.ac.uk/research/genomic_imprinting/

Chotalia M., Smallwood S.A., Ruf N., Dawson C., Lucifero D., Frontera M., James K., Dean W., Kelsey G. Transcription is required for establishment of germline methylation marks at imprinted genes. Genes Dev. 2009;23:105–117. doi: 10.1101/gad.495809. PubMed DOI PMC

Barlow D.P. Genomic Imprinting: A Mammalian Epigenetic Discovery Model. Annu. Rev. Genet. 2011;45:379–403. doi: 10.1146/annurev-genet-110410-132459. PubMed DOI

Meng L., Person R.E., Beaudet A.L. Ube3a-ATS is an atypical RNA polymerase II transcript that represses the paternal expression of Ube3a. Hum. Mol. Genet. 2012;21:3001–3012. doi: 10.1093/hmg/dds130. PubMed DOI PMC

Kato Y., Kaneda M., Hata K., Kumaki K., Hisano M., Kohara Y., Okano M., Li E., Nozaki M., Sasaki H. Role of the Dnmt3 family in de novo methylation of imprinted and repetitive sequences during male germ cell development in the mouse. Hum. Mol. Genet. 2007;16:2272–2280. doi: 10.1093/hmg/ddm179. PubMed DOI

Russo S., Calzari L., Mussa A., Mainini E., Cassina M., Di Candia S., Clementi M., Guzzetti S., Tabano S., Miozzo M., et al. A multi-method approach to the molecular diagnosis of overt and borderline 11p15.5 defects underlying Silver–Russell and Beckwith–Wiedemann syndromes. Clin. Epigenetics. 2016;8:23. doi: 10.1186/s13148-016-0183-8. PubMed DOI PMC

Wilkins J.F., Úbeda F. Chapter 13—Diseases Associated with Genomic Imprinting. In: Cheng X., Blumenthal R.M., editors. Progress in Molecular Biology and Translational Science. Vol. 101. Academic Press; Cambridge, MA, USA: 2011. pp. 401–445. PubMed

Eggermann T., Netchine I., Temple I.K., Tümer Z., Monk D., Mackay D., Grønskov K., Riccio A., Linglart A., Maher E.R. Congenital imprinting disorders: EUCID.net—A network to decipher their aetiology and to improve the diagnostic and clinical care. Clin. Epigenetics. 2015;7:23. doi: 10.1186/s13148-015-0050-z. PubMed DOI PMC

Heerboth S., Lapinska K., Snyder N., Leary M., Rollinson S., Sarkar S. Use of epigenetic drugs in disease: An overview. Genet. Epigenetics. 2014;1:9–19. doi: 10.4137/GEG.S12270. PubMed DOI PMC

Ptak C., Petronis A. Epigenetics and Complex Disease: From Etiology to New Therapeutics. Annu. Rev. Pharmacol. Toxicol. 2008;48:257–276. doi: 10.1146/annurev.pharmtox.48.113006.094731. PubMed DOI

El Bahhaj F., Dekker F.J., Martinet N., Bertrand P. Delivery of epidrugs. Drug Discov. Today. 2014;19:1337–1352. doi: 10.1016/j.drudis.2014.03.017. PubMed DOI

Thakore P.I., D’Ippolito A.M., Song L., Safi A., Shivakumar N.K., Kabadi A.M., Reddy T.E., Crawford G.E., Gersbach C.A. Highly specific epigenome editing by CRISPR-Cas9 repressors for silencing of distal regulatory elements. Nat. Methods. 2015;12:1143–1149. doi: 10.1038/nmeth.3630. PubMed DOI PMC

Liao H.K., Hatanaka F., Araoka T., Reddy P., Wu M.Z., Sui Y., Yamauchi T., Sakurai M., O’Keefe D.D., Núñez-Delicado E., et al. In Vivo Target Gene Activation via CRISPR/Cas9-Mediated Trans-epigenetic Modulation. Cell. 2017;171:1495–1507.e15. doi: 10.1016/j.cell.2017.10.025. PubMed DOI PMC

Chavez A., Scheiman J., Vora S., Pruitt B.W., Tuttle M., P R Iyer E., Lin S., Kiani S., Guzman C.D., Wiegand D.J., et al. Highly efficient Cas9-mediated transcriptional programming. Nat. Methods. 2015;12:326–328. doi: 10.1038/nmeth.3312. PubMed DOI PMC

Morita S., Noguchi H., Horii T., Nakabayashi K., Kimura M., Okamura K., Sakai A., Nakashima H., Hata K., Nakashima K., et al. Targeted DNA demethylation in vivo using dCas9-peptide repeat and scFv-TET1 catalytic domain fusions. Nat. Biotechnol. 2016;34:1060–1065. doi: 10.1038/nbt.3658. PubMed DOI

Gilbert L.A., Larson M.H., Morsut L., Liu Z., Brar G.A., Torres S.E., Stern-Ginossar N., Brandman O., Whitehead E.H., Doudna J.A., et al. XCRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes. Cell. 2013;154:442. doi: 10.1016/j.cell.2013.06.044. PubMed DOI PMC

Pflueger C., Tan D., Swain T., Nguyen T., Pflueger J., Nefzger C., Polo J.M., Ford E., Lister R. A modular dCas9-SunTag DNMT3A epigenome editing system overcomes pervasive off-target activity of direct fusion dCas9-DNMT3A constructs. Genome Res. 2018;28:1193–1206. doi: 10.1101/gr.233049.117. PubMed DOI PMC

Wu Z., Yang H., Colosi P. Effect of genome size on AAV vector packaging. Mol. Ther. 2010;18:80–86. doi: 10.1038/mt.2009.255. PubMed DOI PMC

Grieger J.C., Samulski R.J. Packaging Capacity of Adeno-Associated Virus Serotypes: Impact of Larger Genomes on Infectivity and Postentry Steps. J. Virol. 2005;79:9933–9944. doi: 10.1128/JVI.79.15.9933-9944.2005. PubMed DOI PMC

Saleh A.F., Lázaro-Ibáñez E., Forsgard M.A.M., Shatnyeva O., Osteikoetxea X., Karlsson F., Heath N., Ingelsten M., Rose J., Harris J., et al. Extracellular vesicles induce minimal hepatotoxicity and immunogenicity. Nanoscale. 2019;11:6990–7001. doi: 10.1039/C8NR08720B. PubMed DOI

Matharu N., Rattanasopha S., Tamura S., Maliskova L., Wang Y., Bernard A., Hardin A., Eckalbar W.L., Vaisse C., Ahituv N. CRISPR-mediated activation of a promoter or enhancer rescues obesity caused by haploinsufficiency. Science. 2019;363:eaau0629. doi: 10.1126/science.aau0629. PubMed DOI PMC

György B., Fitzpatrick Z., Crommentuijn M.H.W., Mu D., Maguire C.A. Naturally enveloped AAV vectors for shielding neutralizing antibodies and robust gene delivery in vivo. Biomaterials. 2014;35:7598–7609. doi: 10.1016/j.biomaterials.2014.05.032. PubMed DOI PMC

Colella P., Ronzitti G., Mingozzi F. Emerging Issues in AAV-Mediated In Vivo Gene Therapy. Mol. Ther. Methods Clin. Dev. 2018;8:87–104. doi: 10.1016/j.omtm.2017.11.007. PubMed DOI PMC

Braun S.M.G., Kirkland J.G., Chory E.J., Husmann D., Calarco J.P., Crabtree G.R. Rapid and reversible epigenome editing by endogenous chromatin regulators. Nat. Commun. 2017;8 doi: 10.1038/s41467-017-00644-y. PubMed DOI PMC

MacLeod R.S., Cawley K.M., Gubrij I., Nookaew I., Onal M., O’Brien C.A. Effective CRISPR interference of an endogenous gene via a single transgene in mice. Sci. Rep. 2019;9:1–12. doi: 10.1038/s41598-019-53611-6. PubMed DOI PMC

Hilton I.B., D’Ippolito A.M., Vockley C.M., Thakore P.I., Crawford G.E., Reddy T.E., Gersbach C.A. Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates genes from promoters and enhancers. Nat. Biotechnol. 2015;33:510–517. doi: 10.1038/nbt.3199. PubMed DOI PMC

Kearns N.A., Pham H., Tabak B., Genga R.M., Silverstein N.J., Garber M., Maehr R. Functional annotation of native enhancers with a Cas9-histone demethylase fusion. Nat. Methods. 2015;12:401–403. doi: 10.1038/nmeth.3325. PubMed DOI PMC

Stepper P., Kungulovski G., Jurkowska R.Z., Chandra T., Krueger F., Reinhardt R., Reik W., Jeltsch A., Jurkowski T.P. Efficient targeted DNA methylation with chimeric dCas9-Dnmt3a-Dnmt3L methyltransferase. Nucleic Acids Res. 2017;45:1703–1713. doi: 10.1093/nar/gkw1112. PubMed DOI PMC

Cano-Rodriguez D., Gjaltema R.A.F., Jilderda L.J., Jellema P., Dokter-Fokkens J., Ruiters M.H.J., Rots M.G. Writing of H3K4Me3 overcomes epigenetic silencing in a sustained but context-dependent manner. Nat. Commun. 2016;7:1–11. doi: 10.1038/ncomms12284. PubMed DOI PMC

Rivenbark A.G., Stolzenburg S., Beltran A.S., Yuan X., Rots M.G., Strahl B.D., Blancafort P. Epigenetic reprogramming of cancer cells via targeted DNA methylation. Epigenetics. 2012;7:350–360. doi: 10.4161/epi.19507. PubMed DOI PMC

Bernstein D.L., Le Lay J.E., Ruano E.G., Kaestner K.H. TALE-mediated epigenetic suppression of CDKN2A increases replication in human fibroblasts. J. Clin. Invest. 2015;125:1998–2006. doi: 10.1172/JCI77321. PubMed DOI PMC

Chen H., Kazemier H.G., De Groote M.L., Ruiters M.H.J., Xu G.-L., Rots M.G. Induced DNA demethylation by targeting Ten-Eleven Translocation 2 to the human ICAM-1 promoter. Nucleic Acids Res. 2014;42:1563–1574. doi: 10.1093/nar/gkt1019. PubMed DOI PMC

Maeder M.L., Angstman J.F., Richardson M.E., Linder S.J., Cascio V.M., Tsai S.Q., Ho Q.H., Sander J.D., Reyon D., Bernstein B.E., et al. Targeted DNA demethylation and activation of endogenous genes using programmable TALE-TET1 fusion proteins. Nat. Biotechnol. 2013;31:1137–1142. doi: 10.1038/nbt.2726. PubMed DOI PMC

Huang Y.-H., Su J., Lei Y., Brunetti L., Gundry M.C., Zhang X., Jeong M., Li W., Goodell M.A. DNA epigenome editing using CRISPR-Cas SunTag-directed DNMT3A. Genome Biol. 2017;18:176. doi: 10.1186/s13059-017-1306-z. PubMed DOI PMC

Xu X., Tao Y., Gao X., Zhang L., Li X., Zou W., Ruan K., Wang F., Xu G., Hu R. A CRISPR-based approach for targeted DNA demethylation. Cell Discov. 2016;2:16009. doi: 10.1038/celldisc.2016.9. PubMed DOI PMC

Zalatan J.G., Lee M.E., Almeida R., Gilbert L.A., Whitehead E.H., La Russa M., Tsai J.C., Weissman J.S., Dueber J.E., Qi L.S., et al. Engineering Complex Synthetic Transcriptional Programs with CRISPR RNA Scaffolds. Cell. 2015;160:339–350. doi: 10.1016/j.cell.2014.11.052. PubMed DOI PMC

Qi L., Lo A. Genetic and epigenetic control of gene expression by CRISPR-Cas systems. F1000Research. 2017;6:747. doi: 10.12688/f1000research.11113.1. PubMed DOI PMC

Xu X., Tan X., Tampe B., Wilhelmi T., Hulshoff M.S., Saito S., Moser T., Kalluri R., Hasenfuss G., Zeisberg E.M., et al. High-fidelity CRISPR/Cas9- based gene-specific hydroxymethylation rescues gene expression and attenuates renal fibrosis. Nat. Commun. 2018;9:1–15. doi: 10.1038/s41467-018-05766-5. PubMed DOI PMC

Amabile A., Migliara A., Capasso P., Biffi M., Cittaro D., Naldini L., Lombardo A. Inheritable Silencing of Endogenous Genes by Hit-and-Run Targeted Epigenetic Editing. Cell. 2016;167:219–232.e14. doi: 10.1016/j.cell.2016.09.006. PubMed DOI PMC

Williams R.M., Senanayake U., Artibani M., Taylor G., Wells D., Ahmed A.A., Sauka-Spengler T. Genome and epigenome engineering CRISPR toolkit for in vivo modulation of cis-regulatory interactions and gene expression in the chicken embryo. Development. 2018;145 doi: 10.1242/dev.160333. PubMed DOI PMC

Shi Y., Lan F., Matson C., Mulligan P., Whetstine J.R., Cole P.A., Casero R.A., Shi Y. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell. 2004;119:941–953. doi: 10.1016/j.cell.2004.12.012. PubMed DOI

Kwon D.Y., Zhao Y.T., Lamonica J.M., Zhou Z. Locus-specific histone deacetylation using a synthetic CRISPR-Cas9-based HDAC. Nat. Commun. 2017;8:15315. doi: 10.1038/ncomms15315. PubMed DOI PMC

Hirai H., Tani T., Kikyo N. Structure and functions of powerful transactivators: VP16, MyoD and FoxA. Int. J. Dev. Biol. 2011;54:1589–1596. doi: 10.1387/ijdb.103194hh. PubMed DOI PMC

Cheng A.W., Wang H., Yang H., Shi L., Katz Y., Theunissen T.W., Rangarajan S., Shivalila C.S., Dadon D.B., Jaenisch R. Multiplexed activation of endogenous genes by CRISPR-on, an RNA-guided transcriptional activator system. Cell Res. 2013;23:1163–1171. doi: 10.1038/cr.2013.122. PubMed DOI PMC

Konermann S., Brigham M.D., Trevino A.E., Joung J., Abudayyeh O.O., Barcena C., Hsu P.D., Habib N., Gootenberg J.S., Nishimasu H., et al. Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex. Nature. 2015;517:583–588. doi: 10.1038/nature14136. PubMed DOI PMC

Chavez A., Tuttle M., Pruitt B.W., Ewen-Campen B., Chari R., Ter-Ovanesyan D., Haque S.J., Cecchi R.J., Kowal E.J.K., Buchthal J., et al. Comparison of Cas9 activators in multiple species. Nat. Methods. 2016;13:563–567. doi: 10.1038/nmeth.3871. PubMed DOI PMC

Campa C.C., Weisbach N.R., Santinha A.J., Incarnato D., Platt R.J. Multiplexed genome engineering by Cas12a and CRISPR arrays encoded on single transcripts. Nat. Methods. 2019;16:887–893. doi: 10.1038/s41592-019-0508-6. PubMed DOI

Qi L.S., Larson M.H., Gilbert L.A., Doudna J.A., Weissman J.S., Arkin A.P., Lim W.A. Repurposing CRISPR as an RNA-Guided Platform for Sequence-Specific Control of Gene Expression. Cell. 2013;152:1173–1183. doi: 10.1016/j.cell.2013.02.022. PubMed DOI PMC

Gasperini M., Hill A.J., McFaline-Figueroa J.L., Martin B., Kim S., Zhang M.D., Jackson D., Leith A., Schreiber J., Noble W.S., et al. A Genome-wide Framework for Mapping Gene Regulation via Cellular Genetic Screens. Cell. 2019;176:377–390.e19. doi: 10.1016/j.cell.2018.11.029. PubMed DOI PMC

Li K., Liu Y., Cao H., Zhang Y., Gu Z., Liu X., Yu A., Kaphle P., Dickerson K.E., Ni M., et al. Interrogation of enhancer function by enhancer-targeting CRISPR epigenetic editing. Nat. Commun. 2020;11:1–16. doi: 10.1038/s41467-020-14362-5. PubMed DOI PMC

Connoly J.B. Lentiviruses in gene therapy clinical reseach. Gene Ther. 2002;9:1730–1734. doi: 10.1038/sj.gt.3301893. PubMed DOI

Yáñez-Muñoz R.J., Balaggan K.S., MacNeil A., Howe S.J., Schmidt M., Smith A.J., Buch P., MacLaren R.E., Anderson P.N., Barker S.E., et al. Effective gene therapy with nonintegrating lentiviral vectors. Nat. Med. 2006;12:348–353. doi: 10.1038/nm1365. PubMed DOI

Wold W., Toth K. Adenovirus Vectors for Gene Therapy, Vaccination and Cancer Gene Therapy. Curr. Gene Ther. 2014;13:421–433. doi: 10.2174/1566523213666131125095046. PubMed DOI PMC

Naso M.F., Tomkowicz B., Perry W.L., Strohl W.R. Adeno-Associated Virus (AAV) as a Vector for Gene Therapy. BioDrugs. 2017;31:317–334. doi: 10.1007/s40259-017-0234-5. PubMed DOI PMC

Landegger L.D., Pan B., Askew C., Wassmer S.J., Gluck S.D., Galvin A., Taylor R., Forge A., Stankovic K.M., Holt J.R., et al. A synthetic AAV vector enables safe and efficient gene transfer to the mammalian inner ear. Nat. Biotechnol. 2017;35:280–284. doi: 10.1038/nbt.3781. PubMed DOI PMC

Grieger J.C., Choi V.W., Samulski R.J. Production and characterization of adeno-associated viral vectors. Nat. Protoc. 2006;1:1412–1428. doi: 10.1038/nprot.2006.207. PubMed DOI

Hudry E., Andres-Mateos E., Lerner E.P., Volak A., Cohen O., Hyman B.T., Maguire C.A., Vandenberghe L.H. Efficient Gene Transfer to the Central Nervous System by Single-Stranded Anc80L65. Mol. Ther. Methods Clin. Dev. 2018;10:197–209. doi: 10.1016/j.omtm.2018.07.006. PubMed DOI PMC

Hoffmann M.D., Aschenbrenner S., Grosse S., Rapti K., Domenger C., Fakhiri J., Mastel M., Orner K.B., Eils R., Grimm D., et al. Cell-specific CRISPR-Cas9 activation by microRNA-dependent expression of anti-CRISPR proteins. Nucleic Acids Res. 2019;47:75. doi: 10.1093/nar/gkz271. PubMed DOI PMC

Thakore P.I., Kwon J.B., Nelson C.E., Rouse D.C., Gemberling M.P., Oliver M.L., Gersbach C.A. RNA-guided transcriptional silencing in vivo with S. aureus CRISPR-Cas9 repressors. Nat. Commun. 2018;9:1674. doi: 10.1038/s41467-018-04048-4. PubMed DOI PMC

Chew W.L., Tabebordbar M., Cheng J.K.W., Mali P., Wu E.Y., Ng A.H.M., Zhu K., Wagers A.J., Church G.M. A multifunctional AAV–CRISPR–Cas9 and its host response. Nat. Methods. 2016 doi: 10.1038/nmeth.3993. PubMed DOI PMC

Vogt S., Stadlmayr G., Grillari J., Rüker F., Wozniak-Knopp G. Current Topics in Biochemical Engineering. IntechOpen; London UK: 2019. Engineering of Surface Proteins in Extracellular Vesicles for Tissue-Specific Targeting.

Göran Ronquist K. Extracellular vesicles and energy metabolism. Clin. Chim. Acta. 2019;488:116–121. doi: 10.1016/j.cca.2018.10.044. PubMed DOI

Van Gestel M.A., Boender A.J., De Vrind V.A.J., Garner K.M., Luijendijk M.C.M., Adan R.A.H. Recombinant adeno-associated virus: Efficient transduction of the rat VMH and clearance from blood. PLoS ONE. 2014;9:e97639. doi: 10.1371/journal.pone.0097639. PubMed DOI PMC

Maguire C.A., Balaj L., Sivaraman S., Crommentuijn M.H.W., Ericsson M., Mincheva-Nilsson L., Baranov V., Gianni D., Tannous B.A., Sena-Esteves M., et al. Microvesicle-associated AAV vector as a novel gene delivery system. Mol. Ther. 2012;20:960–971. doi: 10.1038/mt.2011.303. PubMed DOI PMC

Polstein L.R., Gersbach C.A. A light-inducible CRISPR-Cas9 system for control of endogenous gene activation. Nat. Chem. Biol. 2015;11:198–200. doi: 10.1038/nchembio.1753. PubMed DOI PMC

Nihongaki Y., Yamamoto S., Kawano F., Suzuki H., Sato M. CRISPR-Cas9-based photoactivatable transcription system. Chem. Biol. 2015;22:169–174. doi: 10.1016/j.chembiol.2014.12.011. PubMed DOI

Bubeck F., Hoffmann M.D., Harteveld Z., Aschenbrenner S., Bietz A., Waldhauer M.C., Börner K., Fakhiri J., Schmelas C., Dietz L., et al. Engineered anti-CRISPR proteins for optogenetic control of CRISPR–Cas9. Nat. Methods. 2018;15:924–927. doi: 10.1038/s41592-018-0178-9. PubMed DOI

Zetsche B., Volz S.E., Zhang F. A split-Cas9 architecture for inducible genome editing and transcription modulation. Nat. Biotechnol. 2015;33:139–142. doi: 10.1038/nbt.3149. PubMed DOI PMC

Gao Y., Xiong X., Wong S., Charles E.J., Lim W.A., Qi L.S. Complex transcriptional modulation with orthogonal and inducible dCas9 regulators. Nat. Methods. 2016;13:1043–1049. doi: 10.1038/nmeth.4042. PubMed DOI PMC

Tague E.P., Dotson H.L., Tunney S.N., Sloas D.C., Ngo J.T. Chemogenetic control of gene expression and cell signaling with antiviral drugs. Nat. Methods. 2018;15:519–522. doi: 10.1038/s41592-018-0042-y. PubMed DOI PMC

Maji B., Moore C.L., Zetsche B., Volz S.E., Zhang F., Shoulders M.D., Choudhary A. Multidimensional chemical control of CRISPR-Cas9. Nat. Chem. Biol. 2017;13:9–11. doi: 10.1038/nchembio.2224. PubMed DOI PMC

Stojic L., Lun A.T.L., Mangei J., Mascalchi P., Quarantotti V., Barr A.R., Bakal C., Marioni J.C., Gergely F., Odom D.T. Specificity of RNAi, LNA and CRISPRi as loss-of-function methods in transcriptional analysis. Nucleic Acids Res. 2018;46:5950–5966. doi: 10.1093/nar/gky437. PubMed DOI PMC

Kampmann M. CRISPRi and CRISPRa screens in mammalian cells for precision biology and medicine HHS Public Access. ACS Chem. Biol. 2018;13:406–416. doi: 10.1021/acschembio.7b00657. PubMed DOI PMC

Van Buggenhout G., Fryns J.-P. Angelman syndrome (AS, MIM 105830) Eur. J. Hum. Genet. 2009;17:1367–1373. doi: 10.1038/ejhg.2009.67. PubMed DOI PMC

Williams C.A., Driscoll D.J., Dagli A.I. Clinical and genetic aspects of Angelman syndrome. Genet. Med. 2010;12:385–395. doi: 10.1097/GIM.0b013e3181def138. PubMed DOI

Sandanam T., Beange H., Robson L., Woolnough H., Buchholz T., Smith A. Manifestations in institutionalised adults with Angelman syndrome due to deletion. Am. J. Med. Genet. 1997;70:415–420. doi: 10.1002/(SICI)1096-8628(19970627)70:4<415::AID-AJMG16>3.0.CO;2-K. PubMed DOI

Malcolm S., Clayton-Smith J., Nichols M., Pembrey M.E., Armour J.A.L., Jeffreys A.J., Robb S., Webb T. Uniparental paternal disomy in Angelman’s syndrome. Lancet. 1991;337:694–697. doi: 10.1016/0140-6736(91)90278-W. PubMed DOI

Buiting K., Groß S., Lich C., Gillessen-Kaesbach G., El-Maarri O., Horsthemke B. Epimutations in Prader-Willi and Angelman Syndromes: A Molecular Study of 136 Patients with an Imprinting Defect. Am. J. Hum. Genet. 2003;72:571–577. doi: 10.1086/367926. PubMed DOI PMC

Matsuura T., Sutcliffe J.S., Fang P., Galjaard R.-J., Jiang Y., Benton C.S., Rommens J.M., Beaudet A.L. De novo truncating mutations in E6-AP ubiquitin-protein ligase gene (UBE3A) in Angelman syndrome. Nat. Genet. 1997;15:74–77. doi: 10.1038/ng0197-74. PubMed DOI

Kishino T., Lalande M., Wagstaff J. UBE3A/E6-AP mutations cause Angelman syndrome. Nat. Genet. 1997;15:70–73. doi: 10.1038/ng0197-70. PubMed DOI

Dittrich B., Robinson W.P., Knoblauch H., Buiting K., Schmidt K., Gillessen-Kaesbach G., Horsthemke B. Molecular diagnosis of the Prader-Willi and Angelman syndromes by detection of parent-of-origin specific DNA methylation in 15q11-13. Hum. Genet. 1992;90:313–315. doi: 10.1007/BF00220089. PubMed DOI

Kantor B., Kaufman Y., Makedonski K., Razin A., Shemer R. Establishing the epigenetic status of the Prader–Willi/Angelman imprinting center in the gametes and embryo. Hum. Mol. Genet. 2004;13:2767–2779. doi: 10.1093/hmg/ddh290. PubMed DOI

Rougeulle C., Cardoso C., Fontés M., Colleaux L., Lalande M. An imprinted antisense RNA overlaps UBE3A and a second maternally expressed transcript. Nat. Genet. 1998;19:15–16. doi: 10.1038/ng0598-15. PubMed DOI

Silva-Santos S., van Woerden G.M., Bruinsma C.F., Mientjes E., Jolfaei M.A., Distel B., Kushner S.A., Elgersma Y. Ube3a reinstatement identifies distinct developmental windows in a murine Angelman syndrome model. J. Clin. Invest. 2015;125:2069–2076. doi: 10.1172/JCI80554. PubMed DOI PMC

Huang H.-S., Allen J.A., Mabb A.M., King I.F., Miriyala J., Taylor-Blake B., Sciaky N., Dutton J.W., Jr., Lee H.-M., Chen X., et al. Topoisomerase inhibitors unsilence the dormant allele of Ube3a in neurons. Nature. 2011;481:185–189. doi: 10.1038/nature10726. PubMed DOI PMC

Meng L., Ward A.J., Chun S., Bennett C.F., Beaudet A.L., Rigo F. Towards a therapy for Angelman syndrome by targeting a long non-coding RNA. Nature. 2015;518:409–412. doi: 10.1038/nature13975. PubMed DOI PMC

Daily J.L., Nash K., Jinwal U., Golde T., Rogers J., Peters M.M., Burdine R.D., Dickey C., Banko J.L., Weeber E.J. Adeno-Associated Virus-Mediated Rescue of the Cognitive Defects in a Mouse Model for Angelman Syndrome. PLoS ONE. 2011;6:e27221. doi: 10.1371/journal.pone.0027221. PubMed DOI PMC

Bird L.M., Tan W.-H., Bacino C.A., Peters S.U., Skinner S.A., Anselm I., Barbieri-Welge R., Bauer-Carlin A., Gentile J.K., Glaze D.G., et al. A therapeutic trial of pro-methylation dietary supplements in Angelman syndrome. Am. J. Med. Genet. A. 2011;155A:2956–2963. doi: 10.1002/ajmg.a.34297. PubMed DOI PMC

Bi X., Sun J., Ji A.X., Baudry M. Potential therapeutic approaches for Angelman syndrome. Expert Opin. Ther. Targets. 2016;20:601–613. doi: 10.1517/14728222.2016.1115837. PubMed DOI PMC

Vojta A., Dobrinić P., Tadić V., Bočkor L., Korać P., Julg B., Klasić M., Zoldoš V. Repurposing the CRISPR-Cas9 system for targeted DNA methylation. Nucleic Acids Res. 2016;44:5615–5628. doi: 10.1093/nar/gkw159. PubMed DOI PMC

Kim S.-J., Miller J.L., Kuipers P.J., German J.R., Beaudet A.L., Sahoo T., Driscoll D.J. Unique and atypical deletions in Prader–Willi syndrome reveal distinct phenotypes. Eur. J. Hum. Genet. 2012;20:283–290. doi: 10.1038/ejhg.2011.187. PubMed DOI PMC

Wang S.E., Jiang Y. Potential of Epigenetic Therapy for Prader-Willi Syndrome. Trends Pharmacol. Sci. 2019;40:605–608. doi: 10.1016/j.tips.2019.07.002. PubMed DOI

Tan Q., Potter K.J., Burnett L.C., Orsso C.E., Inman M., Ryman D.C., Haqq A.M. Prader–Willi-Like Phenotype Caused by an Atypical 15q11.2 Microdeletion. Genes. 2020;11:128. doi: 10.3390/genes11020128. PubMed DOI PMC

Bazeley P.S., Shepelev V., Talebizadeh Z., Butler M.G., Fedorova L., Filatov V., Fedorov A. snoTARGET shows that human orphan snoRNA targets locate close to alternative splice junctions. Gene. 2008;408:172–179. doi: 10.1016/j.gene.2007.10.037. PubMed DOI PMC

Sahoo T., del Gaudio D., German J.R., Shinawi M., Peters S.U., Person R.E., Garnica A., Cheung S.W., Beaudet A.L. Prader-Willi phenotype caused by paternal deficiency for the HBII-85 C/D box small nucleolar RNA cluster. Nat. Genet. 2008;40:719–721. doi: 10.1038/ng.158. PubMed DOI PMC

De Smith A.J., Purmann C., Walters R.G., Ellis R.J., Holder S.E., Van Haelst M.M., Brady A.F., Fairbrother U.L., Dattani M., Keogh J.M., et al. A deletion of the HBII-85 class of small nucleolar RNAs (snoRNAs) is associated with hyperphagia, obesity and hypogonadism. Hum. Mol. Genet. 2009;18:3257–3265. doi: 10.1093/hmg/ddp263. PubMed DOI PMC

Duker A.L., Ballif B.C., Bawle E.V., Person R.E., Mahadevan S., Alliman S., Thompson R., Traylor R., Bejjani B.A., Shaffer L.G., et al. Paternally inherited microdeletion at 15q11.2 confirms a significant role for the SNORD116 C/D box snoRNA cluster in Prader–Willi syndrome. Eur. J. Hum. Genet. 2010;18:1196–1201. doi: 10.1038/ejhg.2010.102. PubMed DOI PMC

Bieth E., Eddiry S., Gaston V., Lorenzini F., Buffet A., Conte Auriol F., Molinas C., Cailley D., Rooryck C., Arveiler B., et al. Highly restricted deletion of the SNORD116 region is implicated in Prader–Willi Syndrome. Eur. J. Hum. Genet. 2015;23:252–255. doi: 10.1038/ejhg.2014.103. PubMed DOI PMC

Butler M.G., Christian S.L., Kubota T., Ledbetter D.H. A 5-year-old white girl with Prader-Willi syndrome and a submicroscopic deletion of chromosome 15q11q13. Am. J. Med. Genet. 1996;65:137–141. doi: 10.1002/(SICI)1096-8628(19961016)65:2<137::AID-AJMG11>3.0.CO;2-R. PubMed DOI PMC

Burnett L.C., LeDuc C.A., Sulsona C.R., Paull D., Rausch R., Eddiry S., Carli J.F.M., Morabito M.V., Skowronski A.A., Hubner G., et al. Deficiency in prohormone convertase PC1 impairs prohormone processing in Prader-Willi syndrome. J. Clin. Invest. 2017;127:293–305. doi: 10.1172/JCI88648. PubMed DOI PMC

Heksch R., Kamboj M., Anglin K., Obrynba K. Review of Prader-Willi syndrome: The endocrine approach. Transl. Pediatr. 2017;6:274–285. doi: 10.21037/tp.2017.09.04. PubMed DOI PMC

Vogels A., De Hert M., Descheemaeker M.J., Govers V., Devriendt K., Legius E., Prinzie P., Fryns J.P. Psychotic disorders in Prader–Willi syndrome. Am. J. Med. Genet. Part A. 2004;127A:238–243. doi: 10.1002/ajmg.a.30004. PubMed DOI

Costa R.A., Ferreira I.R., Cintra H.A., Gomes L.H.F., Guida L.d.C. Genotype-Phenotype Relationships and Endocrine Findings in Prader-Willi Syndrome. Front. Endocrinol. (Lausanne) 2019;10:864. doi: 10.3389/fendo.2019.00864. PubMed DOI PMC

Cruvinel E., Budinetz T., Germain N., Chamberlain S., Lalande M., Martins-Taylor K. Reactivation of maternal SNORD116 cluster via SETDB1 knockdown in Prader-Willi syndrome iPSCs. Hum. Mol. Genet. 2014;23:4674–4685. doi: 10.1093/hmg/ddu187. PubMed DOI PMC

Li H., Rauch T., Chen Z.X., Szabó P.E., Riggs A.D., Pfeifer G.P. The histone methyltransferase SETDB1 and the DNA methyltransferase DNMT3A interact directly and localize to promoters silenced in cancer cells. J. Biol. Chem. 2006;281:19489–19500. doi: 10.1074/jbc.M513249200. PubMed DOI

Langouët M., Glatt-Deeley H.R., Chung M.S., Dupont-Thibert C.M., Mathieux E., Banda E.C., Stoddard C.E., Crandall L., Lalande M. Zinc finger protein 274 regulates imprinted expression of transcripts in Prader-Willi syndrome neurons. Hum. Mol. Genet. 2017;27:505–515. doi: 10.1093/hmg/ddx420. PubMed DOI

Kim Y., Lee H.-M., Xiong Y., Sciaky N., Hulbert S.W., Cao X., Everitt J.I., Jin J., Roth B.L., Jiang Y. Targeting the histone methyltransferase G9a activates imprinted genes and improves survival of a mouse model of Prader–Willi syndrome. Nat. Med. 2017;23:213–222. doi: 10.1038/nm.4257. PubMed DOI PMC

Temple I.K., Gardner R.J., Robinson D.O., Kibirige M.S., Ferguson A.W., Baum J.D., Barber J.C.K., James R.S., Shield J.P.H. Further Evidence for an Imprinted Gene for Neonatal Diabetes Localised to Chromosome 6q22–q23. Hum. Mol. Genet. 1996;5:1117–1121. doi: 10.1093/hmg/5.8.1117. PubMed DOI

Shield J.P., Gardner R.J., Wadsworth E.J., Whiteford M.L., James R.S., Robinson D.O., Baum J.D., Temple I.K. Aetiopathology and genetic basis of neonatal diabetes. Arch. Dis. Child. Fetal Neonatal Ed. 1997;76:F39–F42. doi: 10.1136/fn.76.1.F39. PubMed DOI PMC

Gardner R.J., Mackay D.J.G., Mungall A.J., Polychronakos C., Siebert R., Shield J.P.H., Temple I.K., Robinson D.O. An imprinted locus associated with transient neonatal diabetes mellitus. Hum. Mol. Genet. 2000;9:589–596. doi: 10.1093/hmg/9.4.589. PubMed DOI

Pivnick E.K., Qumsiyeh M.B., Tharapel A.T., Summitt J.B., Wilroy R.S. Partial duplication of the long arm of chromosome 6: A clinically recognisable syndrome. J. Med. Genet. 1990;27:523–526. doi: 10.1136/jmg.27.8.523. PubMed DOI PMC

Temple I.K., Shield J.P.H. 6q24 transient neonatal diabetes. Rev. Endocr. Metab. Disord. 2010;11:199–204. doi: 10.1007/s11154-010-9150-4. PubMed DOI

Kamiya M., Judson H., Okazaki Y., Kusakabe M., Muramatsu M., Takada S., Takagi N., Arima T., Wake N., Kamimura K., et al. The cell cycle control gene ZAC/PLAGL1 is imprinted—a strong candidate gene for transient neonatal diabetes. Hum. Mol. Genet. 2000;9:453–460. doi: 10.1093/hmg/9.3.453. PubMed DOI

Mackay D., Coupe A.M., Shield J., Storr J., Temple I., Robinson D. Relaxation of imprinted expression of ZAC and HYMAI in a patient with transient neonatal diabetes mellitus. Hum. Genet. 2002;110:139–144. doi: 10.1007/s00439-001-0671-5. PubMed DOI

Arima T., Yamasaki K., John R.M., Kato K., Sakumi K., Nakabeppu Y., Wake N., Kono T. The human HYMAI/PLAGL1 differentially methylated region acts as an imprint control region in mice. Genomics. 2006;88:650–658. doi: 10.1016/j.ygeno.2006.07.005. PubMed DOI

Abdollahi A. LOT1 (ZAC1/PLAGL1) and its family members: Mechanisms and functions. J. Cell. Physiol. 2007;210:16–25. doi: 10.1002/jcp.20835. PubMed DOI

Rodríguez-Henche N., Jamen F., Leroy C., Bockaert J., Brabet P. Transcription of the mouse PAC1 receptor gene: Cell-specific expression and regulation by Zac1. Biochim. Biophys. Acta Gene Struct. Expr. 2002;1576:157–162. PubMed

Arima T., Drewell R.A., Oshimura M., Wake N., Surani M.A. A Novel Imprinted Gene, HYMAI, Is Located within an Imprinted Domain on Human Chromosome 6 Containing ZAC. Genomics. 2000;67:248–255. doi: 10.1006/geno.2000.6266. PubMed DOI

Yorifuji T., Higuchi S., Hosokawa Y., Kawakita R. Chromosome 6q24-related diabetes mellitus. Clin. Pediatr. Endocrinol. 2018;27:59–65. doi: 10.1297/cpe.27.59. PubMed DOI PMC

Zhang M., Chen X., Shen S., Li T., Chen L., Hu M., Cao L., Cheng R., Zhao Z., Luo F. Sulfonylurea in the treatment of neonatal diabetes mellitus children with heterogeneous genetic backgrounds. J. Pediatr. Endocrinol. Metab. 2015;28:877. doi: 10.1515/jpem-2014-0429. PubMed DOI

Fu J.-L., Wang T., Xiao X.-H. Relapsed 6q24-related transient neonatal diabetes mellitus successfully treated with sulfonylurea. Chin. Med. J. (Engl.) 2019;132:846–848. doi: 10.1097/CM9.0000000000000147. PubMed DOI PMC

Abu-Amero S., Monk D., Frost J., Preece M., Stanier P., Moore G.E. The genetic aetiology of Silver-Russell syndrome. J. Med. Genet. 2008;45:193–199. doi: 10.1136/jmg.2007.053017. PubMed DOI

Wakeling E.L., Brioude F., Lokulo-Sodipe O., O’Connell S.M., Salem J., Bliek J., Canton A.P.M., Chrzanowska K.H., Davies J.H., Dias R.P., et al. Diagnosis and management of Silver–Russell syndrome: First international consensus statement. Nat. Rev. Endocrinol. 2017;13:105–124. doi: 10.1038/nrendo.2016.138. PubMed DOI

Gicquel C., Rossignol S., Cabrol S., Houang M., Steunou V., Barbu V., Danton F., Thibaud N., Merrer M.L., Burglen L., et al. Epimutation of the telomeric imprinting center region on chromosome 11p15 in Silver-Russell syndrome. Nat. Genet. 2005;37:1003–1007. doi: 10.1038/ng1629. PubMed DOI

Netchine I., Rossignol S., Dufourg M.-N., Azzi S., Rousseau A., Perin L., Houang M., Steunou V., Esteva B., Thibaud N., et al. 11p15 Imprinting Center Region 1 Loss of Methylation Is a Common and Specific Cause of Typical Russell-Silver Syndrome: Clinical Scoring System and Epigenetic-Phenotypic Correlations. J. Clin. Endocrinol. Metab. 2007;92:3148–3154. doi: 10.1210/jc.2007-0354. PubMed DOI

Azzi S., Rossignol S., Steunou V., Sas T., Thibaud N., Danton F., Le Jule M., Heinrichs C., Cabrol S., Gicquel C., et al. Multilocus methylation analysis in a large cohort of 11p15-related foetal growth disorders (Russell Silver and Beckwith Wiedemann syndromes) reveals simultaneous loss of methylation at paternal and maternal imprinted loci. Hum. Mol. Genet. 2009;18:4724–4733. doi: 10.1093/hmg/ddp435. PubMed DOI

Gaston V., Le Bouc Y., Soupre V., Burglen L., Donadieu J., Oro H., Audry G., Vazquez M.-P., Gicquel C. Analysis of the methylation status of the KCNQ1OT and H19 genes in leukocyte DNA for the diagnosis and prognosis of Beckwith–Wiedemann syndrome. Eur. J. Hum. Genet. 2001;9:409–418. doi: 10.1038/sj.ejhg.5200649. PubMed DOI

Pianka M.A., McIntosh A.T., Patel S.D., Bakhshi P.R., Jung M. Close yet so far away: A look into the management strategies of genetic imprinting disorders. Am. J. Stem Cells. 2018;7:72–81. PubMed PMC

Eggermann T., Begemann M., Binder G., Spengler S. Silver-Russell syndrome: Genetic basis and molecular genetic testing. Orphanet J. Rare Dis. 2010;5:19. doi: 10.1186/1750-1172-5-19. PubMed DOI PMC

Saal H.M., Harbison M.D., Netchine I. Silver-Russell Syndrome. In: Adam M.P., Ardinger H.H., Pagon R.A., Wallace S.E., Bean L.J.H., Stephens K., Amemiya A., editors. GeneReviews((R)) University of Washington; Seattle, WA, USA: 1993. PubMed

Han L., Szabó P.E., Mann J.R. Postnatal Survival of Mice with Maternal Duplication of Distal Chromosome 7 Induced by a Igf2/H19 Imprinting Control Region Lacking Insulator Function. PLoS Genet. 2010;6:e1000803. doi: 10.1371/journal.pgen.1000803. PubMed DOI PMC

Ablation of Gabra5 Influences Corticosterone Levels and Anxiety-like Behavior in Mice

Generation and Characterization of a Novel Angelman Syndrome Mouse Model with a Full Deletion of the Ube3a Gene